URSO, Luca
 Distribuzione geografica
Continente #
NA - Nord America 2.536
AS - Asia 2.438
EU - Europa 1.054
SA - Sud America 504
AF - Africa 58
OC - Oceania 9
Totale 6.599
Nazione #
US - Stati Uniti d'America 2.395
SG - Singapore 1.189
CN - Cina 427
BR - Brasile 424
IT - Italia 383
HK - Hong Kong 297
VN - Vietnam 220
DE - Germania 179
GB - Regno Unito 101
CA - Canada 65
RU - Federazione Russa 65
FI - Finlandia 62
MX - Messico 61
ID - Indonesia 59
NL - Olanda 49
IN - India 45
AT - Austria 34
JP - Giappone 32
PL - Polonia 32
AR - Argentina 29
SE - Svezia 27
BD - Bangladesh 25
ES - Italia 24
FR - Francia 21
LT - Lituania 20
IQ - Iraq 19
ZA - Sudafrica 18
IR - Iran 17
TR - Turchia 17
EC - Ecuador 16
KR - Corea 15
UA - Ucraina 13
BE - Belgio 11
MA - Marocco 11
CO - Colombia 10
IL - Israele 9
PK - Pakistan 9
PY - Paraguay 9
TH - Thailandia 9
CZ - Repubblica Ceca 8
UZ - Uzbekistan 7
EG - Egitto 6
GR - Grecia 6
MY - Malesia 6
SA - Arabia Saudita 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
DZ - Algeria 5
CR - Costa Rica 4
KE - Kenya 4
QA - Qatar 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
AO - Angola 3
CL - Cile 3
KG - Kirghizistan 3
RO - Romania 3
SN - Senegal 3
TW - Taiwan 3
UY - Uruguay 3
AZ - Azerbaigian 2
BH - Bahrain 2
CH - Svizzera 2
CY - Cipro 2
ET - Etiopia 2
HU - Ungheria 2
IS - Islanda 2
NI - Nicaragua 2
PE - Perù 2
PT - Portogallo 2
RS - Serbia 2
TV - Tuvalu 2
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
BO - Bolivia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PW - Palau 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
Totale 6.599
Città #
Singapore 690
Ashburn 448
Dallas 323
Hong Kong 297
Santa Clara 235
Beijing 197
Los Angeles 125
New York 123
Ho Chi Minh City 74
Munich 68
Chicago 65
Chandler 60
Hanoi 52
Hefei 51
Jakarta 49
Milan 41
São Paulo 39
Mexico City 37
Shanghai 36
Bologna 34
Ferrara 33
Buffalo 32
Atlanta 30
Brooklyn 30
Houston 29
London 29
Warsaw 28
Frankfurt am Main 26
Lappeenranta 26
Tokyo 25
Helsinki 23
Denver 22
Montreal 22
Nuremberg 22
Phoenix 21
Orem 20
Stockholm 20
Fairfield 19
Rome 19
Poplar 18
Falkenstein 16
Rio de Janeiro 16
Brasília 15
Salt Lake City 15
Toronto 15
Boston 14
The Dalles 14
Vienna 14
Turku 13
Council Bluffs 12
Dong Ket 12
Manchester 12
Moscow 12
Chennai 11
Haiphong 11
Johannesburg 11
Ottawa 11
Seattle 11
Amsterdam 10
Boardman 10
Elk Grove Village 10
Brussels 9
Porto Alegre 9
Ankara 8
Assago 8
Belo Horizonte 8
Buriram 8
City of London 8
Mumbai 8
Parma 8
Wilmington 8
Da Nang 7
Kansas City 7
San Francisco 7
Tashkent 7
Thái Nguyên 7
Asunción 6
Cambridge 6
Campinas 6
Ferrara di Monte Baldo 6
Istanbul 6
Princeton 6
Querétaro 6
Quito 6
Secaucus 6
Tampa 6
Athens 5
Berlin 5
Bremen 5
Brno 5
Cairo 5
Curitiba 5
Dulles 5
Düsseldorf 5
Guayaquil 5
Manaus 5
Miami 5
Poggio Renatico 5
San Diego 5
San Jose 5
Totale 4.050
Nome #
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 183
90 Y/177 Lu‐dotatoc From Preclinical Studies to Application in Humans 171
Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma 164
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 157
MONTE CARLO SIMULATIONS IN RADIO-LIGAND THERAPY WITH LU-177 FOR NEUROENDOCRINE TUMOURS (NETS) 135
18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients 133
The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review 130
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 125
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study) 122
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE 120
Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial 119
[18F]FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake 117
PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature 114
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study 113
Role of 18F-FDG PET/CT in evaluating lymph node status in patients with head and neck squamous cell carcinoma 109
Uncommon solitary nasal extramedullary plasmacytoma detected by 18F-FDG PET/CT 109
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 109
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer 108
Relevance of Volumetric Parameters Applied to [68Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT 107
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 106
Rhenium Radioisotopes for Medicine, a Focus on Production and Applications 103
Is There a Role for FAPI PET in Urological Cancers? 103
Positron Emission Tomography-Derived Radiomics and Artificial Intelligence in Multiple Myeloma: State-of-the-Art 103
The Role of [18F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach 103
FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature 99
Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) 98
PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review 97
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer 96
Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report 95
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 95
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 94
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 94
68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors 93
Cavernous Hepatic Hemangioma at 18F‑Choline Positron Emission Tomography–Computed Tomography: Be Aware of the Pitfall 90
COMPARISON BETWEEN CLINICAL DOSIMETRIC PLATFORMS IN NET PATIENTS TREATED WITH PRRT 90
[18F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review 90
18F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy 90
Complicated Inguinal Hernia Incidentally Detected on a Radiolabelled Autologous White Blood Cell Scan 89
Superscan-Like Pattern on 18F-Choline PET/CT in a Patient With Essential Thrombocythemia 88
68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives 87
99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications 86
Incidental findings of acute myeloid leukemia in Sjögren's syndrome detected by nuclear medicine techniques 86
18 F-Choline Versus 68 Ga-PSMA-11 PET/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma 83
Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review 82
Considerations on the preliminary results of the NETTER-2 trial: is the glass half full or half empty? 78
[99mTc]Tc-sestamibi for the differential diagnosis of renal masses: a study protocol 77
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer 75
Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report 74
Diagnostic Accuracy of PET with 18F-Fluciclovine ([18F]FACBC) in Detecting High-Grade Gliomas: A Systematic Review and Meta-Analysis 74
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study 74
Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives 70
18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study 64
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer 63
Radiomics Results for Adrenal Mass Characterization Are Stable and Reproducible Under Different Software 63
Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives 61
The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness 59
The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria 57
Lymphoid organs’ metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study 56
Extramedullary disease in multiple myeloma: what you might not expect on [18F]FDG PET/CT - a pictorial essay 55
Insights into pet-based radiogenomics in oncology: an updated systematic review 53
Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study 53
PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality? 52
Artificial intelligence & nuclear medicine: an emerging partnership 50
Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000-2022) 50
The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential 49
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors 48
Clinical applications of long axial field-of-view PET/CT scanners in oncology 48
Molecular imaging of PARP in cancer: state-of-the-art 47
Triple Tracer PET in Advanced Prostate Cancer: Chasing Phenotypic Plasticity 47
Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine? 44
The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective 44
Initial results of the use of a novel semiquantitative parameter in three-phase bone scan to predict 99mTc-HMPAO-labeled leukocyte scintigraphy in patients with unilateral total knee replacement 43
The Future Direction of Women in Nuclear Medicine and Nuclear Medicine in Women's Health 41
The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review 40
Phosphorus-32 microparticles for locally advanced pancreatic cancer: how and when? 39
Synthetic imaging for research and education in nuclear medicine: Who’s afraid of the black box? 39
PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview 39
Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach 34
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON? 30
One scan, many stories: deep learning for signal separation in multi-tracer PET imaging 29
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 26
Safire CT iterative reconstruction protocol to reduce patient effective dose on PET/CT examinations 24
Radioligand Therapy with Radiolabeled Somatostatin Analogues in Metastatic Bronchial Carcinoid: an Impressive Response 24
18 F-FDG PET/CT Volumetric Metabolic Parameters in the Staging of Head and Neck Squamous Cell Carcinoma 20
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy 20
Radionuclide-based nanotechnologies in triple-negative breast cancer: current evidence and future perspectives 15
Molecular Imaging in Cancer Chemoresistance: What’s Brewing? 15
Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights 11
Totale 6.859
Categoria #
all - tutte 35.118
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.118


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202162 0 0 0 0 0 32 1 5 0 5 1 18
2021/202261 2 0 0 2 5 4 7 2 5 3 15 16
2022/2023186 7 15 3 17 21 20 18 18 14 2 42 9
2023/2024371 11 24 29 14 40 45 12 47 18 12 40 79
2024/20252.312 74 87 190 104 235 144 87 110 369 304 357 251
2025/20263.866 609 308 687 908 979 375 0 0 0 0 0 0
Totale 6.859